GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

New resource highlights critical role of lifestyle interventions in maximizing weight loss success and addressing limitations of GLP-1 therapiesMONTREAL, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ideal ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...

Biomea Fusion (BMEA) announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th ...